GHSR-1a comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-31. Numbers and descriptions here follow the published literature rather than marketing material.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
== Endurance sports == The use of performance-enhancing drugs in sport has become an increasing problem across a wide range of sports. It is defined as any substance or drug that, when taken, gives an athlete an unfair advantage relative to a "clean" athlete. The banning of these drugs promotes a level playing field and equality among athletes. The use of 'the suit' in swimming, which gives athletes an advantage in the way of hydrodynamics, has been banned from international competition due to the unfair advantage it delivered. The drugs taken by athletes differ widely based on the performance needs of the sport. Erythropoietin (EPO) is largely taken by endurance athletes who seek a higher level of red blood cells, which leads to more oxygenated blood, and a higher VO2 max. An athlete's VO2 max is highly correlated with success within endurance sports such as swimming, long-distance running, cycling, rowing, and cross-country skiing. EPO has recently become prevalent amongst endurance athletes due to its potency and low degree of detectability when compared to other methods of doping such as blood transfusion. While EPO is believed to have been widely used by athletes in the 1990s, there was not a way to directly test for the drug until 2002 as there was no specific screening process to test athletes. Athletes at the Olympic Games are tested for EPO through blood and urine tests. Stringent guidelines and regulations can lessen the danger of doping that has existed within some endurance sports. A notable case being TJ Dillashaw.
== Diagnosis == Substance use disorders can be confused with other psychiatric disorders. There are diagnoses for substance-induced mood disorders and substance-induced anxiety disorders and thus such overlap can be complicated. For this reason, the DSM-IV advises that diagnoses of primary psychiatric disorders not be made in the absence of sobriety (of a duration sufficient to allow for any substance-induced post-acute-withdrawal symptoms to dissipate) up to 1 year.
=== Rites of passage and belonging === Traditionally, the most common reason for scarification has been as a rite of passage. Scarification has been widely used by many West African tribes to mark milestone stages in both men and women's lives, such as puberty and marriage. In many tribes, members unwilling to participate in scarification were generally not included in the group's activities, and are often shunned from their society. According to anthropologist Grace Harris, group members lacking the normal characteristics consistent with the group are not considered as having acquired the full standing as agents in their society; they would also lack the capacity for meaningful behavior, such as greeting, commanding, and stating. Therefore, scarification can transform partial tribe members into "normal" members entirely accepted by the group. Scarification is a form of language not readily expressed, except through extensive and intricate greetings, and gives the ability to communicate fully, which is a key element for being considered as a normal member of the group. One reason why scarification is used as confirmation of adulthood is how it shows the ability to endure pain. With young men, the endurance of the pain of scarring exhibits strength and discipline, especially in tribes where males have roles as hunters and warriors. A young man who has already experienced the feeling of torn or cut flesh is considered less likely to fear the teeth of a wild animal or the tip of an enemy's spear.
The band's second album, Darklands, was released during the tour, in September, described by writer Steve Taylor as "the definitive blend of light and shade". Featuring a more melodic sound, the album was recorded almost entirely by the Reids themselves, replacing live drums with a drum machine, and received overwhelmingly positive reviews by the British music press. The album's title track was released as a single in October, and the band were thrown off the ITV music show The Roxy when they failed to mime well enough to it. The band's dangerous reputation culminated at a gig at the RPM club in Toronto in November 1987, when after being heckled throughout the gig by a group in the audience, Jim Reid thrust his microphone stand towards them, hitting one on the head. Jim was arrested and spent a night in jail, before being bailed to return the following February. He was subsequently given an absolute discharge after agreeing to give around £500 to a Salvation Army charity and apologise to the complainant. With the court case hanging over the band, they compiled a collection of B-sides and rarities for release in April 1988 as Barbed Wire Kisses. They also selected live tracks from a Detroit concert the previous November for release while they planned further studio work. Dave Evans, former Mary Chain soundman and bass player with Biff Bang Pow! (which also featured Alan McGee and Dick Green of Creation Records) was recruited in September 1987 to replace Moore, who formed John Moore and the Expressway. Richard Thomas joined on drums in early 1988.
== Structure == Alginic acid is a linear copolymer with homopolymeric blocks of (1→4)-linked β-D-mannuronate (M) and α-L-guluronate (G) residues, respectively, covalently linked together in different sequences or blocks. The monomers may appear in homopolymeric blocks of consecutive G-residues (G-blocks), consecutive M-residues (M-blocks) or alternating M and G-residues (MG-blocks). α-L-guluronate is the C-5 epimer of β-D-mannuronate.
Sources: en.wikipedia.org
The Basuto's lack of cooperation gave rise to calls for Basutoland's disannexation within the Cape Parliament. Eager to restore pre-war order, Scanlen invited Major General Charles George Gordon to Basutoland. Gordon had built a reputation as a capable administrator and an expert negotiator. He proposed replacing the magisterial system, granting the Basuto chiefs de facto autonomous rule. The proposal was rejected by John X. Merriman as unenforceable, citing the absence of unity among the Basuto. Merriman persuaded Gordon to stay in the Cape for an additional year. Sauer and Gordon then traveled to Basutoland in September 1882, Gordon was convinced that he could resolve the conflict if he were to enter negotiations with Masopha. On 16 September, Sauer held a private meeting with Letsie I and Lerotholi, and consented to the Basuto chiefs' proposal to assemble a force against Masopha. On 25 September, Gordon departed for a meeting with Masopha at Thaba Bosiu, at the same time Lerotholi had completed preparations to launch an assault on the stronghold. During his meeting with Masopha, Gordon disobeyed written instructions given to him by Sauer. Furthermore, Masopha intentionally prolonged the negotiations, thus thwarting Lerotholi's assault on the mountain. Gordon departed Thaba Bosiu without having achieved his objective and resigned soon afterwards. Lerotholi felt humiliated by the incident, which developed into a long-lasting rivalry between him and his uncle.
semiconservative replication The standard mode of DNA replication that occurs in all living cells, in which each of the two parental strands of the original double-stranded DNA molecule are used as template strands, with DNA polymerases replicating each strand separately and simultaneously in antiparallel directions. The result is that each of the two double-stranded daughter molecules is composed of one of the original parental strands and one newly synthesized complementary strand, such that each daughter molecule conserves the precise sequence of information (indeed the very same atoms) from one-half of the original molecule. Contrast conservative replication and dispersive replication.
In a 1951 letter to the publisher Milton Waldman (1895–1976), Tolkien wrote about his intentions to create a "body of more or less connected legend", of which "[t]he cycles should be linked to a majestic whole, and yet leave scope for other minds and hands, wielding paint and music and drama". The hands and minds of many artists have indeed been inspired by Tolkien's legends. Personally known to him were Pauline Baynes (Tolkien's favourite illustrator of The Adventures of Tom Bombadil and Farmer Giles of Ham) and Donald Swann (who set the music to The Road Goes Ever On). Queen Margrethe II of Denmark created illustrations to The Lord of the Rings in the early 1970s. She sent them to Tolkien, who was struck by the similarity they bore in style to his own drawings. Tolkien was not implacably opposed to the idea of a dramatic adaptation, however, and sold the film, stage and merchandise rights of The Hobbit and The Lord of the Rings to United Artists in 1968. United Artists never made a film, although the director John Boorman was planning a live-action film in the early 1970s. In 1976 the rights were sold to Tolkien Enterprises, a division of the Saul Zaentz Company, and the first film adaptation of The Lord of the Rings was released in 1978 as an animated rotoscoping film directed by Ralph Bakshi with screenplay by the fantasy writer Peter S. Beagle. It covered only the first half of the story of The Lord of the Rings.
=== Differential diagnosis === About 99% of HD diagnoses based on the typical symptoms and a family history of the disease are confirmed by genetic testing to have the expanded trinucleotide repeat that causes HD. Most of the remaining are called HD-like (HDL) syndromes. The cause of most HDL diseases is unknown, but those with known causes are due to mutations in the prion protein gene (HDL1), the junctophilin 3 gene (HDL2), a recessively inherited unknown gene (HDL3—only found in two families and poorly understood), and the gene encoding the TATA box-binding protein (SCA17, sometimes called HDL4). Other autosomal dominant diseases that can be misdiagnosed as HD are dentatorubral-pallidoluysian atrophy and neuroferritinopathy. Also, some autosomal recessive disorders resemble sporadic cases of HD. These include chorea acanthocytosis and pantothenate kinase-associated neurodegeneration. One X-linked disorder of this type is McLeod syndrome.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.